REFERENCES
1. Hafiane A, Genest J. High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. BBA Clin 2015;3:175-88.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
3. Ramirez A, Hu PP. Low high-density lipoprotein and risk of myocardial infarction. Clin Med Insights Cardiol 2015;9:113-7.
4. Annema W, von Eckardstein A. Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy. Transl Res 2016;173:30-57.
5. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, Wu Y, Buffa J, Kim T, Gerstenecker GS, Gu X, Kadiyala CS, Wang Z, Culley MK, Hazen JE, Didonato AJ, Fu X, Berisha SZ, Peng D, Nguyen TT, Liang S, Chuang CC, Cho L, Plow EF, Fox PL, Gogonea V, Tang WH, Parks JS, Fisher EA, Smith JD, Hazen SL. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014;20:193-203.
6. Khine HW, Teiber JF, Haley RW, Khera A, Ayers CR, Rohatgi A. Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: observations from the dallas heart study. Atherosclerosis 2017;263:156-62.
7. Mackness M, Mackness B. Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene 2015;567:12-21.
8. Perła-Kaján J, Jakubowski H. Paraoxonase 1 and homocysteine metabolism. Amino Acids 2012;43:1405-17.
9. Ben-David M, Elias M, Filippi JJ, Du-ach E, Silman I, Sussman JL, Tawfik DS. Catalytic versatility and backups in enzyme active sites: the case of serum paraoxonase 1. J Mol Biol 2012;418:181-96.
11. Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X, Fu X, Wagner MA, Besler C, Gerstenecker G, Zhang R, Li XM, DiDonato AJ, Gogonea V, Tang WH, Smith JD, Plow EF, Fox PL, Shih DM, Lusis AJ, Fisher EA, DiDonato JA, Landmesser U, Hazen SL. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 2013;123:3815-28.
12. Harangi M, Mirdamadi HZ, Seres I, Sztanek F, Molnár M, Kassai A, Derdák Z, Illyés L, Paragh G. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity. Transl Res 2009;153:190-8.
13. Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res 2015;60:50-73.
14. Balogh Z, Seres I, Harangi M, Kovács P, Kakuk G, Paragh G. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Diabetes Metab 2001;27:604-10.
15. Nakou ES, Filippatos TD, Kiortsis DN, Derdemezis CS, Tselepis AD, Mikhailidis DP, Elisaf MS. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 2008;9:3151-8.
16. Harangi M, Seres I, Harangi J, Paragh G. Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment. Cardiovasc Drugs Ther 2009;23:501-10.
17. Smolen A, Eckerson HW, Gan KN, Hailat N, La Du BN. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab Dispos 1991;19:107-12.
18. Schaefer EJ, Anthanont P, Asztalos BF. High-density lipoprotein metabolism, composition, function, and deficiency. Curr Opin Lipidol 2014;25:194-9.
19. Li JJ, Zhang Y, Li S, Cui CJ, Zhu CG, Guo YL, Wu NQ, Xu RX, Liu G, Dong Q, Sun J. Large HDL subfraction but not HDL-C is closely linked with risk factors, coronary severity and outcomes in a cohort of nontreated patients with stable coronary artery disease: a prospective observational study. Medicine (Baltimore) 2016;95:e2600.
20. Soran H, Schofield JD, Durrington PN. Antioxidant properties of HDL. Front Pharmacol 2015;6:222.
21. Wang M, Lang X, Cui S, Zou L, Cao J, Wang S, Wu X. Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease risk. DNA Cell Biol 2012;31:975-82.
22. Mackness B, Turkie W, Mackness M. Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease. Arch Med Sci 2013;9:8-13.
23. Hernández-Díaz Y, Tovilla-Zárate CA, Juárez-Rojop IE, González-Castro TB, Rodríguez-Pérez C, López-Narváez ML, Rodríguez-Pérez JM, Cámara-álvarez JF. Effects of paraoxonase 1 gene polymorphisms on heart diseases: systematic review and meta-analysis of 64 case-control studies. Medicine (Baltimore) 2016;95:e5298.
24. Zhou B, Zu L, Chen Y, Zheng X, Wang Y, Pan B, Dong M, Zhou E, Zhao M, Zhang Y, Zheng L, Gao W. Myeloperoxidase-oxidized high density lipoprotein impairs atherosclerotic plaque stability by inhibiting smooth muscle cell migration. Lipids Health Dis 2017;16:3.
25. Teng N, Maghzal GJ, Talib J, Rashid I, Lau AK, Stocker R. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox Rep 2017;22:51-73.
26. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, Simoons ML, Hamm CW; CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5.
27. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604.
28. Szentpéteri A, Zsíros N, Varga VE, Lőrincz H, Katkó M, Seres I, Fülöp P, Paragh G, Harangi M. Paraoxonase-1 and myeloperoxidase correlate with vascular biomarkers in overweight patients with newly diagnosed untreated hyperlipidaemia. Vasa 2017;46:370-6.
29. Zsíros N, Koncsos P, Lőrincz H, Seres I, Katkó M, Szentpéteri A, Varga VE, Fülöp P, Paragh G, Harangi M. Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications. Clin Biochem 2016;49:862-7.
30. Haraguchi Y, Toh R, Hasokawa M, Nakajima H, Honjo T, Otsui K, Mori K, Miyamoto-Sasaki M, Shinohara M, Nishimura K, Ishida T, Hirata K. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. Atherosclerosis 2014;234:288-94.
